CN116783199A - 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物 - Google Patents

作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物 Download PDF

Info

Publication number
CN116783199A
CN116783199A CN202180089379.6A CN202180089379A CN116783199A CN 116783199 A CN116783199 A CN 116783199A CN 202180089379 A CN202180089379 A CN 202180089379A CN 116783199 A CN116783199 A CN 116783199A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
represented
bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180089379.6A
Other languages
English (en)
Chinese (zh)
Inventor
B·T·霍普金斯
B·马
I·马克斯
J·舒尔茨
G·万德维尔
R·普林斯
M·内瓦莱宁
T·陈
Z·尤萨夫
M·希梅尔鲍尔
V·帕塔罗彭
J·H·琼斯
E·Y·林
F·冈萨雷斯洛佩兹德图里索
T·普吉特
A·G·卡帕奇
S·夏博拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bojian Massachusetts Co ltd
Original Assignee
Bojian Massachusetts Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bojian Massachusetts Co ltd filed Critical Bojian Massachusetts Co ltd
Publication of CN116783199A publication Critical patent/CN116783199A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180089379.6A 2020-11-13 2021-11-12 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物 Pending CN116783199A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113515P 2020-11-13 2020-11-13
US63/113,515 2020-11-13
PCT/US2021/059168 WO2022104079A1 (en) 2020-11-13 2021-11-12 Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors

Publications (1)

Publication Number Publication Date
CN116783199A true CN116783199A (zh) 2023-09-19

Family

ID=78828007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180089379.6A Pending CN116783199A (zh) 2020-11-13 2021-11-12 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物

Country Status (14)

Country Link
US (1) US20240083900A1 (https=)
EP (1) EP4244223A1 (https=)
JP (1) JP7839790B2 (https=)
KR (1) KR20230119134A (https=)
CN (1) CN116783199A (https=)
AR (1) AR124048A1 (https=)
AU (1) AU2021377891A1 (https=)
BR (1) BR112023009116A2 (https=)
CL (1) CL2023001367A1 (https=)
CO (1) CO2023007677A2 (https=)
MX (1) MX2023005626A (https=)
TW (1) TW202233624A (https=)
UY (1) UY39517A (https=)
WO (1) WO2022104079A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118955332A (zh) * 2024-07-31 2024-11-15 德阳悦合生物医药科技有限公司 一种作为医药中间体的化合物叔丁基甲基(3-酮环丁基)氨基甲酸酯的制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086575A1 (en) * 2021-11-12 2023-05-19 Biogen Ma Inc. Btk inhibitors
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
JP2025515728A (ja) * 2022-05-10 2025-05-20 バイオジェン・エムエイ・インコーポレイテッド Ｎ－メチル－Ｎ－（（１ｓ，３ｓ）－３－メチル－３－（（６－（１－メチル－１Ｈ－ピラゾール－４－イル）ピラゾロ［１，５－ａ］ピラジン－４－イル）オキシ）シクロブチル）アクリルアミドの結晶多形
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
WO2024117205A1 (ja) * 2022-11-30 2024-06-06 北興化学工業株式会社 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤
CN116693357B (zh) * 2023-06-07 2026-01-27 西安工程大学 一种β-三氟甲基不饱和酰胺及其合成方法
WO2025049254A1 (en) * 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911433B2 (en) * 1996-09-27 2005-06-28 The United States Of America As Represented By The Department Of Health And Human Services O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates
CN103987713A (zh) * 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
CN105814057A (zh) * 2013-07-31 2016-07-27 默克专利有限公司 用作btk抑制剂的嘧啶、吡啶和吡嗪及其用途
CN106459045A (zh) * 2014-04-17 2017-02-22 艾伯维公司 杂环激酶抑制剂
CN111285873A (zh) * 2018-12-07 2020-06-16 广东东阳光药业有限公司 Ret抑制剂、其药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2025515728A (ja) * 2022-05-10 2025-05-20 バイオジェン・エムエイ・インコーポレイテッド Ｎ－メチル－Ｎ－（（１ｓ，３ｓ）－３－メチル－３－（（６－（１－メチル－１Ｈ－ピラゾール－４－イル）ピラゾロ［１，５－ａ］ピラジン－４－イル）オキシ）シクロブチル）アクリルアミドの結晶多形

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911433B2 (en) * 1996-09-27 2005-06-28 The United States Of America As Represented By The Department Of Health And Human Services O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates
CN103987713A (zh) * 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
CN105814057A (zh) * 2013-07-31 2016-07-27 默克专利有限公司 用作btk抑制剂的嘧啶、吡啶和吡嗪及其用途
CN106459045A (zh) * 2014-04-17 2017-02-22 艾伯维公司 杂环激酶抑制剂
CN111285873A (zh) * 2018-12-07 2020-06-16 广东东阳光药业有限公司 Ret抑制剂、其药物组合物及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118955332A (zh) * 2024-07-31 2024-11-15 德阳悦合生物医药科技有限公司 一种作为医药中间体的化合物叔丁基甲基(3-酮环丁基)氨基甲酸酯的制备方法

Also Published As

Publication number Publication date
CL2023001367A1 (es) 2024-01-05
JP2023549360A (ja) 2023-11-24
CO2023007677A2 (es) 2023-09-08
TW202233624A (zh) 2022-09-01
BR112023009116A2 (pt) 2023-10-03
AR124048A1 (es) 2023-02-08
MX2023005626A (es) 2023-07-31
KR20230119134A (ko) 2023-08-16
UY39517A (es) 2022-06-30
WO2022104079A1 (en) 2022-05-19
JP7839790B2 (ja) 2026-04-02
US20240083900A1 (en) 2024-03-14
AU2021377891A1 (en) 2023-07-06
EP4244223A1 (en) 2023-09-20
AU2021377891A9 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
JP7540113B1 (ja) Ｂｃｌ－２阻害剤
CN116783199A (zh) 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物
CN103797011B (zh) 作为c-Kit激酶抑制剂的化合物和组合物
KR20260010430A (ko) Kras g12s 및 g12c 억제제
WO2022266258A1 (en) Compounds and methods for the targeted degradation of irak-4
TW202309039A (zh) 用於靶向布魯頓氏酪胺酸激酶降解之化合物
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
EA036172B1 (ru) Спирогептансалициламиды и родственные соединения как ингибиторы rock
MX2013005603A (es) Derivados de pirrolopiridina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
CN116981675A (zh) 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法
WO2023086521A1 (en) Btk inhibitors
JP2023537065A (ja) Ｂｔｋ阻害剤
RU2858502C2 (ru) Производные пиразол[1,5-a]пиразина в качестве ингибиторов втк
CN115279757A (zh) 用于治疗和预防hiv感染的抗病毒药剂的嘧啶系双环化合物
CA3256816A1 (en) LRRK2 INHIBITORS
CN118984829A (zh) Btk抑制剂
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
OA21863A (en) Indazole based compounds and associated methods of use.
KR20260022448A (ko) 디히드로피리미딘-2,4(1h,3h)-디온을 함유하는 폴리시클릭 유도체 및 이의 약학적 조성물, 이의 제조 방법 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination